As PRMT5 is inhibited by the accumulation of the unprocessed MTAP metabolite MTA in tumor cells [11], MTAP deficiency makes these cells more susceptible to PRMT5- or MAT2A-inhibiting drugs (summarized in [7]). The gene discussed is MTAP; the disease is neoplasm.